90

Shanghai Shenqi Pharmaceutical Investment Management Co LtdSHG 900904 Stock Report

Last reporting period 30 Sep, 2023

Updated 23 Oct, 2024

Last price

Market cap $B

0.394

Micro

Exchange

XSHG - Shanghai Stock Exchange

900904.SS Stock Analysis

90

Avoid

Based on Eyestock quantitative analysis, 900904.SS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

41/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

36.8 %

Overvalued

Market cap $B

0.394

Dividend yield

3.53 %

Shares outstanding

534.07 B

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. engages in the research and development, manufacture, and sale of antitumor, cardiovascular, cold and cough, children medicine, and anti fungi drugs. The company is headquartered in Shanghai, Shanghai and currently employs 1,371 full-time employees. is a China-based company principally engaged in research and development, manufacture and sale of pharmaceuticals. The Company’s products are targeted for the treatment of influenza, cardio cerebrovascular diseases, rheumatoid bone diseases and in the areas of oncology, antifungal, antipyretic and gynaecology. The firm's main products include cantharidin sodium vitamin B6 injection, cantharidin sodium injection and other Chinese patent drug products. The firm distributes its products in domestic market.

View Section: Eyestock Rating